Fildena 100 is used to treat medical problems, erectile dysfunction, and pulmonary hypertension. Erectile dysfunction is one of the most common sexual problems in men, and it is defined as a condition in which a man experiences trouble in getting and keeping erections that are sufficient enough to have satisfactory sexual intercourse.
Vidalista 60 Mg is a drug used in the treatment of Erectile Dysfunction and Pulmonary Hypertension.
This medicine must not be used together with drugs that treat pulmonary arterial hypertension like Riociguat.
For More Imformation Visit Our Site : Welloxpharma
Sildenafil citrate is present in fildena 100 as the active agent used primarily for the treatment of erectile dysfunction.
But it is also used in the treatment of some other health problems like pulmonary hypertension.
Do not take any other drug other than this drug.
In addition, excessive drug use can be harmful to your body.
The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025.
PAH occurs when the pulmonary arteries thicken or grow rigid.
These drugs have superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and side-effects.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sampleA new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be launched in 2016 and is likely to drive growth of the prostacyclin and prostacyclin analogs market.
In the U.S., the Orphan Drug Act (ODA) encourages pharmaceutical industries to develop orphan drugs by offering benefits such as tax credits, research grants, and orphan drug exclusivity of seven years.
Transplantation- Lung or heart-lung transplant might be an option especially for younger people who have idiopathic pulmonary arterial hypertension.Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and Rest of the World.
North America held the maximum share of market for PAH in terms of revenue in 2013, which is then followed by Europe.